Trials
3 active
6 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.”In the company’s words, NCT06387069 on ClinicalTrials.gov
- Tested for
- Acute Myeloid Leukemia, Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation, Gliomas Harboring IDH1 and/or IDH2 Mutations
- Main trialPhase 3
- “This study is a multicenter, randomized, open-label, phase III clinical study (RAPHAEL) to evaluate the efficacy, safety, and PK of HMPL-306 versus salvage chemotherapy in patients with R/R AML harboring IDH1 and IDH2 mutations.”In the company’s words, NCT06387069 on ClinicalTrials.gov
Other drugs for Acute Myeloid Leukemia
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- QuizartinibDaiichi Sankyo · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
Coming up3
- DecPhase 1 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- Mar 2032Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2028 | A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia | |
| Phase 3Not yet recruiting | Mar 2032 | HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations | |
| Phase 1Recruiting | Dec 2026 | Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations | |
| Phase 1Terminated | 15 Jan 2025 | A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH | |
| Phase 1Terminated | 27 Feb 2025 | A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations | |
| Phase 1Completed | 28 Feb 2025 | Study on Mass Balance of [14C]HMPL-306(Isocitrate Dehydrogenase Inhibitor) in Healthy Chinese Adult Male Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026